Artiva Biotherapeutics, Inc.

NASDAQ:ARTV

Biotechnology

Healthcare
$3.77 -3.37%

-$0.34 today

Market cap
$186.36M
Beta
2.40
P/E (TTM)
-2.7
EPS (TTM)
-$3.53
52W Low $1.47High $14.53

Volume 0.97M

Average 0.48M

ARTV Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Artiva Biotherapeutics, Inc.NASDAQ: ARTV

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization grows, but more slowly than its trailing trend

Q1 FY2026 depreciation & amortization of $666K rose 6.1% year over year, behind the +9.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 39.3% from the prior quarter. Over 3 fiscal years it compounded at +30.9% a year.

Context

  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +6.1% toward the trailing-twelve-month pace of +9.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$666K-39.3% QoQ
Last fiscal yearDec 2025
$2.6M+6.8% YoY
LTMMar 2026
$2.71M+9.6% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+6.1%——
1 year+6.8%——
3-year CAGR+30.9%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
2.6M USD
Year-over-year change
+6.8%
4-year CAGR
+79.9%

Depreciation & Amortization vs competitors

How ARTV compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +9.6% is the 2nd highest of 9, against a peer median of -14.7%.
  • Over three fiscal years its annual growth of +30.9% compares with a peer median of -2.6%.
ARTV Competitors
Depreciation & Amortization for ARTV and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STROSutro Biopharma, Inc.LTM Mar 2026$6.7M USD-8.9%+8.8%6.7%
STTKShattuck Labs, Inc.LTM Mar 2026$3.64M USD-3.9%+6.3%364.3%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$2.71M USD+9.6%+30.9%—
DTILPrecision BioSciences, Inc.LTM Mar 2026$2.69M USD-30.3%-32.6%6.0%
GUTSFractyl Health, Inc. Common StockLTM Mar 2026$1.12M USD+22.5%+35.7%—
CNTBConnect Biopharma Holdings LimitedFY2025$704K USD+6.7%-11.4%1100.0%
ALXOALX Oncology Holdings Inc.LTM Mar 2026$645K USD-25.8%+27.3%—
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$628K USD-48.8%-19.7%—
IFRXInflaRx N.V.LTM Mar 2026€377.74K EUR-20.5%-12.3%1287.9%
Peer median (excluding ARTV) —-14.7%-2.6%364.3%

Competitors are the stored peer set for ARTV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(71.83M)(58.79M)(28.72M)(65.37M)(83.87M)
Depreciation & Amortization248K1.16M2.27M2.43M2.6M
Deferred Income Tax00000
Stock-Based Compensation4.31M6.58M7.05M6.98M6.82M
Change in Working Capital33.41M(3.87M)(28.28M)(325K)(424K)
Accounts Receivables(468K)(57K)(1.23M)1.61M79K
Inventory00000
Accounts Payables(1.24M)190K(408K)519K(760K)
Other Working Capital35.13M(4M)(26.64M)(2.46M)257K
Other Non-Cash Items18.55M4.08M251K1.26M(1.88M)
Operating Cash Flow(15.3M)(50.83M)(47.43M)(55.03M)(76.75M)
Capital Expenditures(1.72M)(6.3M)(3.26M)(642K)(2.59M)
Acquisitions (Net)00000
Purchases of Investments00(49.52M)(176.17M)(44.88M)
Sales of Investments0026.8M56.35M110.87M
Other Investing Activities00000
Investing Cash Flow(1.72M)(6.3M)(25.98M)(120.46M)63.41M
Debt Repayment000(149K)(132K)
Common Stock Issued000166.51M371K
Common Stock Repurchased0(5K)(12K)(4.18M)0
Dividends Paid00000
Other Financing Activities(1.86M)(1.26M)24.4M51K(230K)
Financing Cash Flow152.75M(1.26M)24.39M162.23M9K
Effect of Forex Changes00000
Net Change in Cash135.73M(58.39M)(49.01M)(13.27M)(13.33M)
Free Cash Flow(17.03M)(57.13M)(50.69M)(55.67M)(79.34M)

Artiva Biotherapeutics, Inc.

NASDAQ:ARTV

Intrinsic Alpha fair value

Locked

Current Price

$3.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.